The following 15 drugs chosen for Medicare negotiation

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts before President-elect Trump’s inauguration.

The Centers for Medicare and Medicaid Services (CMS) had until Feb. 1 to release the list, but officials said the agency had routinely moved forward throughout the process.

Along with the top 10 drugs already negotiated by Medicare, the newest drug selection accounts for one-third of all Medicare Part D spending. Last year’s talks also included some of the manufacturers that will have to negotiate this year.

“Today, I’m proud to announce that my administration has selected the next 15 drugs for Medicare drug price negotiation. The drugs treat conditions like diabetes and cancer, and seniors across the country depend on ‘them,” President Biden said in a statement.

Novo Nordisk, Merck, Boehringer Ingelheim, Pfizer and Bristol Myers Squibb (parent company of Celgene Corp.) will be asked to negotiate with Medicare for the second consecutive year. Manufacturers will have until February 28 to sign bargaining agreements.

Conditions treated with these drugs include diabetes, cancer, chronic obstructive pulmonary disease (COPD), and schizophrenia.

Here are the next 15 drugs chosen for Medicare negotiations:

Ozempic; Rybelsus; Wegovy
To treat: Diabetes, obesity
Manufacturer: Novo Nordisk

Ellipta trilogy
To treat: COPD
Manufacturer: GlaxoSmithKline

Xtandi
To treat: Metastatic castration-resistant prostate cancer
Manufacturer: Astellas Pharma

Reduce speed
To treat: multiple myeloma
Manufacturer: Celgene Corp.

Ibrance
To treat: breast cancer
Manufacturer: Pfizer

Off
To treat: Idiopathic pulmonary fibrosis
Manufacturer: Boehringer Ingelheim

Linzess
To treat: Irritable bowel syndrome with constipation
Manufacturer: Forestry Pharmaceuticals

Calquency
To treat: Mantle cell lymphoma
Manufacturer: AstraZeneca

Austedo; Austedo XR
To treat: Chorea associated with Huntington’s disease, tardive dyskinesia
Manufacturer: Teva Pharmaceuticals

Breo Ellipta
To treat: Airflow obstruction and to reduce exacerbations in patients with COPD
Manufacturer: GlaxoSmithKline

traditional
To treat: Type 2 diabetes mellitus
Manufacturer: Boehringer Ingelheim

Xifaxan
To treat: Travelers’ diarrhea caused by E. coli
Manufacturer: Salix Pharmaceuticals

Vrays
To treat: Schizophrenia, manic episodes associated with bipolar 1 disorder
Manufacturer: you are working

Janumet; Janumet XR
To treat: Type 2 diabetes mellitus
Manufacturer: Merck

Otezla
To treat: Psoriatic arthritis
Manufacturer: Celgene Corp.

Source link